Department of Tumor Process Monitoring and Therapy Design

Head of the Department: Vasyl F. Chekhun
Academic Degree and Title: Doctor of Medical Sciences, Professor, Academician of the National Academy of Sciences of Ukraine
Tel: +38 (044) 259-01-83
E-mail: chekhun@onconet.kiev.ua, chekhun@nas.gov.ua

Priority Research Areas

  • Identification of patterns of stress-induced factors in the tumor microenvironment and substantiation of their feasibility for assessing the risk of cancer progression.
  • Investigation of the molecular and biological features of the synergistic action of individual microbiome components and the immune system in the formation of mechanisms of antitumor resistance.
  • Screening, preclinical and clinical studies of biologically active anticancer compounds of synthetic and natural origin.
  • Study of the molecular mechanisms underlying intrinsic and acquired resistance of tumor cells in in vitro and in vivo systems.
  • The role of bone tissue remodeling markers in determining the degree of malignancy of neoplasms.
  • Molecular epidemiology of metal-containing proteins in normal and transformed cells and their role in shaping tumorhost interactions.
  • Nanosystems for targeted delivery in oncology: molecular mechanisms of interaction and their transformation in biological systems.

Keywords

Personalization of anticancer therapy; molecular markers of drug resistance; morphofunctional and stromal tumor framework; stress-induced factors of carcinogenesis; tumor microenvironment; effectors of innate and adaptive antitumor immunity; breast and prostate cancer; the role of the human microbiome in the tumor process and factors for its modulation; glucose metabolism and its specific features in malignancy; metastatic bone lesions and reparative osteogenesis.

  • Study of the parenchymalstromal component and microenvironmental features of malignant neoplasms of various histogenesis, considering their spatial cytoarchitectonics and the status of opportunistic and saprophytic microbiota.
  • Elucidation of the role of stress-induced markers of the tumor microenvironment and their regulatory factors in the development and progression of the most common hormone-dependent malignancies.
  • Molecular epidemiology of metal-containing proteins in normal and transformed cells and their role in tumorhost interactions.
  • Identification of tumor-associated microRNAs as predictive extratumoral markers and their role in tumorhost interactions.
  • Pharmacological correction of epigenetic disturbances in cellular processes.
  • Nanosystems for targeted delivery in oncology: molecular mechanisms of interaction and their transformation in biological systems.
  • The role of bone tissue remodeling markers in determining tumor malignancy grade.
  • Development of 3D modeling and 3D printing technologies for personalized models of bones affected by malignant neoplasms for surgical planning and intraoperative navigation.
  • Search for and study of natural-origin agents with antitumor and immunomodulatory activity.
  • Determination of the role of representatives of opportunistic and saprophytic human microbiota in the metabolic processes of malignant cells.
  • Development and substantiation of new regimens combining cancer biotherapy agents with traditional methods of clinical oncology.
  • Search for immunological indicators predictive of the efficacy of cancer biotherapy.
  1. Research Project Comprehensive Cancer Infrastructure in Europe (CCI4EU) No. 101103746 HORIZON-MISS-2022-CANCER-01 Horizon Europe Grant Agreement No. 101103746 (dated April 24, 2023), Organisation of European Cancer Institutes (OECI), https://cci4eu.eu/ (20232026).
  2. Research Project Development of a Technology for Identifying Stress-Induced Factors Initiating Metastatic Bone Lesions State Registration No. 0125U000655 (20252026) Scientific and scientific-technical (experimental) work under the priority area Development of Modern Biological and Biomedical Methods, Diagnostic Tools and Technologies to Support the State During Wartime and Postwar Period” (2025–2026).
  1. Rīga Stradiņš University Research Week 2025: Knowledge for Use in Practice. Riga, Latvia, March 26-28, 2025.
  2. Beyond Sciences Initiative 10th International Remote Conference: Science and Society 2025. Virtual Event, Worldwide. February 21-22, 2025.
  3. Assessment of Quality of Life in Cancer Patients Covered in Experimental and Clinical Oncology Publications: Challenges and Opportunities. Kyiv, Ukraine. October 3-4, 2024.
  4. 9th Annual International Remote Conference: Science and Society. Virtual Event, Worldwide. March 2-3 and 23, 2024.
  5. Тhe 7 th Congress of the All-Ukrainian Public Organization «Ukrainian Society of Cell Biology» with international representation, Lviv, Ukraine, September 11-13, 2024.
  6. 7th International Conference “Cancer Immunotherapy and Immunomonitoring (CITIM)”. Vilnius, Lithuania, April 24-27, 2023.
  7. EACR-AstraZeneca Cancer Epigenetics. Virtual Event, Worldwide, December 5-6, 2023.
  8. OECI Oncology Days 45, Paris, June 14-16, 2023.
  9. 22nd PIVAC meeting, Athens, September 28-29, 2023.
  10. ХIX International scientific conference for students and PhD students Youth and progress of biology. Lviv, Ukraine. April 26-28, 2023.
  11. Shevchenkivska vesna: Advancements in Life Science — XX International conference of students and young scientists. Kyiv, Ukraine. April 27-28, 2023.
  12. RSU research week: International Research Conference «Knowledge for Use in Practice». Rīga, Latvia. March 29-31, 2023.
  13. 8th Annual international remote conference: Science and Society. Worldwide: February 25-26 & March 18, 2023.
  14. Riga Stradiņš University International Student Conference in Health and Social Sciences 2022. Riga, Latvia, March 24-25, 2022.
  15. Chance for Science Conference 2022: Conference for academics affected by the war in Ukraine, Leipzig, Germany (Worldwide). September 8-9, 2022.
  16. 7th Annual international remote conference: Science and Society. Worldwide: February 26-27 & March 5, 2022.
  17. The 56th Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI), Bari, Italy, June 8-10, 2022.
  18. EACR-Worldwide Cancer Research Meeting The Structural Microenvironment: Breaking down the walls of cancer. Worldwide. February22-23, 2022.
  19. IV International Scientific Conference Microbiology and Immunology the development outlook in the 21st century. Kyiv, Ukraine, September 22-23, 2022.
  20. XIV Congress of Oncologists and Radiologists of Ukraine, Kyiv, Ukraine. September 30 — October 2, 2022.
  21. The 5th congress of the Serbian association for cancer research with international participation Translational potential of cancer research in Serbia Virtual event, December 3, 2021.
  22. International Scientific and Practical Conference Implementation of modern science and practice, Varna, Bulgaria, 2021.
  23. International Scientific and Practical Conference Multidisciplinary Academic Research and Innovation, Amsterdam, Netherlands, 2021.
  24. International Young Scientists Conference on Molecular and Cell Biology, Warsaw, Poland, February 25-26, 2021.
  25. XVІ International scientific conference for students and PhD students dedicated to the 75th anniversary of the faculty of biology of Ivan Franko national university of Lviv and 90th anniversary from the birthday of prof. M.P. Derkach. Lviv, Ukraine, April 27-29, 2020.
  26. ESCI Virtual Meeting 2020: Covid19 Edition. September 20, 2020.
  27. II International conference Tumor and host: Novel aspects of old problem. Kyiv, Ukraine, November 21-22, 2019.
  28. 6th Ukrainian Congress for Cell Biology with international representation, Yaremche, Ukraine, June 18-21, 2019.
  29. Riga Stradins university international conference on medical and health care sciences Knowledge for use in practice, Riga, Latvia, April 1-3, 2019.
  30. 10th EFIS-EJI South Eastern European Immunology School (SEEIS2018) Yerevan, Armenia, October 19-22, 2018.
  31. 5th European Congress of Immunology. Amsterdam, Netherlands, September 2-5, 2018.
  32. 13th EFIS-EJI Tatra Immunology Conference Molecular Determinants of T-Cell Immunity. trbsk Pleso, Slovakia, June 9-13, 2018.
  33. International VACTRAIN/3-rd Swedish-Ukrainian conference on cancer diseases Stockholm, Sweden, January 16-17, 2017.
  34. 2n EACR-OECI Conference, Amsterdam, Netherlands, March 13-16, 2017.
  35. International Scientific Conference Normal and cancer stem cells: discovery, diagnosis and therapy, Kyiv, Ukraine, October 5-6, 2017.
  36. 12th EFIS-EJI Tatra Immunology Conference. trbsk Pleso, Slovakia, September 3-7, 2016.
  37. International Scientific Conference Integrated clinical and pathogenetic approaches in diagnosis and therapy of cancer, Kyiv, Ukraine, June 13-15, 2016.
  38. XIII Congress of Oncologists and Radiologists of Ukraine, Kyiv, Ukraine. May 26-28, 2016.
  39. International Scientific Conference Targets of immunotherapy of chronic viral infections and cancer. Riga, May 24-26, 2016.
  40. 7th EFIS/EJI South East European Immunology School (SEEIS2015), Becici, Montenegro, October 16-19, 2015.
  1. Chekhun V., Lukianova Ye., Mushii O., Zadvornyi T., Pavlova A., Burda T., Bazas V., Shepelenko I., Lukianova N. Breast cancer microenvironment composition associated with high PD-L1 expression. BMC cancer, 2025. Vоl. 25. https://link.springer.com/journal/12885
  2. Chekhun, V.F., Lukianova, N.Y., Kunska, L.M. Naleskina L. A. Integrated manifestations of cellular stress as a trigger of tumor progression. Cytology and Genetics 2025;59 (4): 388-396 https://www.doi.org/10.3103/S0095452725040048
  3. Chekhun, V., Burda, T., Mushii, O., Pavlova, A., Borikun, T., Zadvornyi, T., Lukianova, N. Stress-induced modulation of the tumor microenvironment: mechanisms and implications for cancer progression. Experimental Oncology 2025;47(2):127-142. https://doi.org/10.15407/exp-oncology.2025.02.127
  4. Kozak, T., Lykhova, O., Chekhun, V. Reprogramming of glucose metabolism in human breast cancer cells after co-cultivation with Bifidobacterium animalis. Experimental Oncology. 2025;47(1): 315. https://doi.org/10.15407/exp-oncology.2025.01.003
  5. Lukianova N., Mushii O., Zadvornyi T., Chekhun V. Development of an algorithm for biomedical image analysis of the spatial organization of collagen in breast cancer tissue of patients with different clinical status. FEBS Open Bio 2024; 14: 675686 https://doi.org/10.1002/2211-5463.13773
  6. Chekhun V., Borikun T., Zadvornyi T., Mushii O., Stakhovsky E., Vitruk Y., Lukianova N. Osteonectin (SPARC) prognostic value in prostate cancer. Pathology-Research and Practice 2024; 254: 155053. https://doi.org/10.1016/j.prp.2023.155053
  7. Drobotun, O., Kolotilov, N., Konovalenko, V., Ternovyy, N. Assessment of the dalargin effect on the level of vitamin D and melatonin in blood serum in patients with malignant bone tumors and polymorbidity. Pain, joints, spine.; 2024. 14(1), 3641. https://doi.org/10.22141/pjs.14.1.2024.411
  8. Drobotun O., Konovalenko S., Ternovyi N. The use of a training 3D-model in the treatment of a patient with a pathological fracture of the proximal part of the femur (case from practice). Оrthopaedics, traumatology and prosthetics. 2024; 1: 53–58. https://doi.org/10.15674/0030-59872024153-58
  9. Drobotun O., Ternovyy N., Konovalenko S., Khmel A. Assessment of the impact of surgical treatment of primary malignant bone tumors on the quality of life of patients in peacetime and in the realities of wartime in Ukraine. Pain, joints. 2024; 14(4): 179-185. https://doi.org/10.22141/pjs.14.4.2024.436
  10. Drobotun, O., Protsenko V.,Ternovyy, N., Improving patients quality of life after surgical treatment of primary malignant bone tumors using a training 3D model. Exp Oncol. 2024; 46(4):341344 https://doi.org/10.15407/exp-oncology.2024.04.341
  11. N.I. Fedosova, A.V. Chumak, N.L. Cheremshenko, O.M. Karaman, T.V. Symchych, I.M. Voyeykova. In vivo study of potential mechanisms of macrophage repolarization on the background of tumor growth. Exp Oncol 2024; 46 (1): 30-37. https://doi.org/10.15407/exp-oncology.2024.01.030
  12. Fedosova N.I., Cheremshenko N.L., Gogol S.V., Bezdieniezhnykh N.O., Tikhonov V.M., Voyeykova I.M., Konovalenko V.F., Chekhun V.F. The influence of Bifidobacterium animalis and lectin of B. subtilis IMV B-7724 on the antitumor immune response of mice with Erhlich adenocarcinoma. Exp Oncol 2024; 46(3): 228-236. https://doi.org/10.15407/exp-oncology.2024.03.228
  13. Chumak A, Fedosova N, Cheremshenko N, et al. Effect of lectin B. subtilis ІМV B-7724 on the activity of the effectors of cellular component of anticancer immunity. Exp Oncol 2023; 45 (3): 328-36. https://doi.org/10.15407/exp-oncology.2023.03.328
  14. Zadvornyi T., Lukianova N., Mushii O., Pavlova A., Voronina O., Chekhun V. Benign and malignant prostate neoplasms show different spatial organization of collagen. Croatian Medical Journal 2023; 64(6): 413-420. https://doi.org/10.3325/cmj.2023.64.413
  15. Lykhova O., Zavelevich M., Philchenkov A., Vidasov N., Kozak T., Lozovska Y., Andrusyshyna I., Anupam Bishayee, Borikun T, Lukianova N, Chekhun, V. (2023). Does insulin make breast cancer cells resistant to doxorubicin toxicity? Naunyn-Schmiedeberg’s Archives of Pharmacology, 396(11), 3111-3122. 10.1007/s00210-023-02516-3
  16. Chumachenko V., Virych P., Nie G., Virych P., Yeshchenko O., Khort P., Tkachenko A., Prokopiuk V., Lukianova N., Zadvornyi T., Rawiso M., Liyao Ding, Kutsevol N. Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro. International Journal of Nanomedicine 2023; 18: 48214838. https://doi.org/10.2147/IJN.S416046
  17. Kozak T, Lykhova O, Serhiichuk T, Bezdieniezhnykh N, Chekhun V. Optimization of experimental model systems for evaluating reciprocal influence of bifidobacterium animalis and human breast cancer cells in vitro. Experimental Oncology. 2023. — 45(4). — Р. 504–514. https://doi.org/10.15407/exp-oncology.2023.04.504
  18. Naleskina, L.A., Lukianova, N.Y., Zadvornyi, T.V., Kunska L.M., Mushii O.M., Chekhun V.F. Remodeling the architecture of collagen-containing connective tissue fibers of metastatic prostate Cancer. Cytology and Genetics 2023; 57: 406412. https://doi.org/10.3103/S0095452723050031
  19. Lukianova N., Zadvornyi T., Kashuba E., Borikun T., Mushii О., Chekhun V. Expression of markers of bone tissue remodeling in breast cancer and prostate cancer cells in vitro. Experimental Oncology 2023; 44(1): 39-46. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17354
  20. Zadvornyi T., Lukianova N., Borikun T., Tymoshenko A., Mushii O., Voronina O., Vitruk I.; Stakhovskyi E., Chekhun V. Mast cells as a tumor microenvironment factor associated with the aggressiveness of prostate cancer. Neoplasma 2022; 69(6): 490-1498. https://doi.org/10.4149/neo_2022_221014N1020
  21. Zadvornyi T., Lukianova N., Borikun T., Gogol S., Virych P., Lykhova O., Chekhun, V. Expression of osteopontin and osteonectin in breast and prostate cancer cells with different sensitivity to doxorubicin. Experimental Oncology 2022; 44(2): 107-112. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17886
  22. Lukianova N., Zadvornyi T., Kashuba E., Borikun T., Mushii О., Chekhun V. Expression of markers of bone tissue remodeling in breast cancer and prostate cancer cells in vitro. Experimental Oncology 2022; 44(1): 39-46. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17354
  23. Kutsevol N., Kuziv Y., Bezugla T., Virych P., Marynin A., Borikun T., Lukianova N., Chekhun V. (2021). Application of new multicomponent nanosystems for overcoming doxorubicin resistance in breast cancer therapy. Applied Nanoscience 2022; 12: 427437. https://doi.org/10.1007/s13204-020-01653-y
  24. Fedosova N.I., Symchych T.V., Cheremshenko N.L., Chumak A.V., Koval E.V., Karaman O.M., Voyeykova I.M. Аntimetastatic effect of B. subtilis IMV B-7724 lectin observed in a Lewis lung carcinoma model. Experimental Oncology 2022; 44(2):155-158. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17914
  25. Kisten O.G., Hetman K.I., Koval E.V., Hretskyi I.O., Zyryanova L.F., Tyshchenko L.M., Fedosova N.I., Cheremshenko N.L., Chumak A.V. Features of the Synthesis of Extracellular Cytotoxic Lectin Bacillus subtilis IMV B-7724, Depending on the Cultivation Conditions in the Laboratory Fermenter. Mikrobiol. Z. 2022; 3: 17-28. https://doi.org/10.15407/microbiolj84.03.017
  26. Fedosova N.I., Symchych T.V., Chumak A.V., Shcherbina V.M., Cheremshenko N.L., Karaman O.M. The effect of B. subtilis ІМV B-7724 lectin on functional activity of the main effectors of antitumor immunity of intact mice. Biotechnol Acta 2022; 15(4): 11-14. https://doi.org/10.15407/exp-oncology.2023.03.328
  27. Symchych T.V., Fedosova N.I., Chumak A.V., Cheremshenko N.L., Karaman O.M. Effects of B. subtilis IMV В-7724 lectin on malignant and normal cells in vitro. Biotechnol Acta 2022; 15(4): 47-49. https://doi.org/10.15407/biotech15.04.047
  28. Sergey Konovalenko, Volodymyr Protsenko, Yevgen Solonitsyn, Taras Osadchuk, Volodymyr Konovalenko, Taras Omelchenko. Effect of bioactive glass-based composite and low energy laser on bone regeneration in an experimentally induced bone defect. Archiv Euromedica. — Hannover: Europashe Wissenschaftliche Gesellschaft e.V.Hannover.- 2022. Vol.12. Num.2. P.75-80. http://dx.doi.org/10.35630/2199-885X/2022/12/2.19
  29. Konovalenko, V., Drobotun, O., Ternovyy, N. Konovalenko, S., Garashchenko, O. Monitoring and personalization in treatment of breast cancer patients with metastatic bone lesions. Eureka: Health Sciences: 2022; 1: 37-48. https://doi.org/10.21303/2504-5679.2022.002270
  30. Konovalenko V.F., Ternovyi N.K., Tuz E.V., Protsenko V.V., Solonitsyn E.O., Audai A., Drobotun O.V., Ulianchych. Experimental substantiation of the use of hydroxyapatite — tricalcium phosphate bioceramics for replacing bone defects after tumor removal. Experimental Oncology. — 2021. – Vol. 43(3). — Р. 237–241. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-3.16584
  31. Bezdieniezhnykh N, Lykhova A, Kozak T, Zadvornyi T, Borikun T, Voronina O, Lukianova N. Assessment of biosafety and toxicity of hydrophilic gel for implantation in experimental in vitro and in vivo models. BMC Pharmacology and Toxicology. 2022. — 23. 37, 1-15. https://doi.org/10.1186/s40360-022-00577-3
  32. Shvets YV, Lykhova OO, Chekhun VF. Human microbiota and breast cancer. Experimental Oncology. – 2022. — 4 (2). — Р. 95-106. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17855
  33. Chumak A.V., Fedosova N.I., Shcherbina V., Cheremshenko N.L., Karaman O.M., Chekhun V.F.. Influence of bacterial lectin on key regulatory links of functional activity of macrophages of mice with ehrlich carcinoma. Exp Oncol 2021; 43:197-203. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-3.16537
  34. Bezdieniezhnykh N, Holiuk Ye, Gerasymenko S, Saulenko K, Mayko V, Lykhova O. Evaluation of in vitro biocompatibility of scaffolds for the repair of bone defects. Cell Organ Transpl. – 2021. — 9(2). – Р. 96-102. https://doi.org/10.22494/cot.v9i2.128
  35. Fedosova N.I., Cheremshenko N.L., Hetman K.I., Symchych T.V., Chumak A.V., Shliahovenko V.O., Voyeykova I.M., Didenko H.V. Physicochemical and cytotoxicity properties of Bacillus subtilis ІМВ В-7724 extracellular lectin. Mikrobiol. Z. 2021; 83(1): 39-48. https://doi.org/10.15407/microbiolj83.01.039
  36. A.V. Chumak, N.I. Fedosova, N.L. Cheremshenko, T.V. Symchych, I.M. Voyeykova, V.F. Chekhun. Macrophage polarization in dynamics of lewis lung carcinoma growth and metastasis. Exp Oncol 2021; 43: 1520. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15829
  37. Zadvornyi T.V., Lukianova N.Y., Borikun T.V., Vitruk Y.V., Stakhovsky E.O., Chekhun V.F. NANOG as prognostic factor of prostate cancer course. Experimental Oncology 2020; 42(2): 94-100. https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14673
  38. Lozovska Y.V., Lukianova N.Y., Todor І.М., Burlaka P., Ganusevych І.І., Chekhun, V.F., Andrusishуna І.М. (2020). Effect of metal ions on functioning of antioxidant system and enzymes of extracellular matrix in tumors differed in their doxorubicin sensitivity. Fiziologichnyi Zhurnal 2020; 66(4): 20-29. https://doi.org/10.15407/fz66.04.020
  39. Chekhun V.F., Borikun T.V., Bazas V.М., Andriiv A.V., Klyusov O.М., Yalovenko T.М., Lukianova N.Y. Association of circulating miR-21,-205, and-182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment. Experimental Oncology 2020; 42(3): 162-166. https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.14805
  40. Symchych T.V., Fedosova N.I., Chumak A.V., Cheremshenko N.L. Karaman О.М. Burlaka А.P., Voyeykova I.M. Functions of tumor-associated macrophages and macrophages residing in remote anatomical niches in Ehrlich carcinoma bearing mice. Exp Oncol 2020; 42(2): 197-203 https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.14928
  41. Fedosova N.I., Cheremshenko N.L., Getman K.I., Karaman O.M., Symchych T.V., Ivanchenko A.V., Danyliuk O.I., Voeykova I.M., Didenko G.V. Bioactivity of the Bacillus subtilis IMV B-7724 Extracellular Lectin. Mikrobiol. Z. 2019; 81(4):107-117. https://doi.org/10.15407/microbiolj81.04.107
  42. Karaman О.М., Ivanchenko A.V., Chekhun V.F. Macrophages — a perspective target for antineoplastic Immunotherapy. Experimental oncology 2019, 41(4): 282-290. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-4.13698
  43. Zadvornyi T.V., Lukianova N.Y., Borikun T.V., Chekhun, V.F. Effects of exogenous lactoferrin on phenotypic profile and invasiveness of human prostate cancer cells (DU145 and LNCaP) in vitro. Experimental oncology 2018; 40(3): 184189. https://doi.org/10.31768/2312-8852.2016.38(3):181-186
  44. Bezdieniezhnykh N., Kovalova O., Lykhova O., Kocherga R., Vorontsova A., Zhylchuk V., Maksimyak G., Kudryavets Yu. Effect of antitumor drugs in low concentrations on the biological, immunophenotypic and cytogenetic characteristics of human colon cancer cells in vitro. Experimental Oncology. 2017 — 39 (1): 1724. https://exp-oncology.com.ua/pdf/2017/39_1/2355.pdf
  45. Naleskina L.A., Lukianova N.Y., Sobchenko S.O., Storchai D.M., Chekhun V.F. Lactoferrin expression in breast cancer in relation to biologic properties of tumors and clinical features of disease. Experimental Oncology 2016: 38(3): 181186. https://exp-oncology.com.ua/pdf/2016/38_3/2301.pdf
  46. Bezdenezhnykh N., Lykhova A., Semesiuk N., Okhrimenko R., Kudryavets Yu. Establishment and characterization of new breast and ovarian cancer cell lines as a model for studying cellular plasticity in vitro. Experimental Oncology. — 2016; 38 (2): 94100. https://exp-oncology.com.ua/pdf/2016/38_2/2271.pdf
  47. Yalovenko T.M., Todor I.M., Lukianova N.Y., Chekhun V.F. Hepcidin as a possible marker in determination of malignancy degree and sensitivity of breast cancer cells to cytostatic drugs. Experimental oncology 2016; 38(2): 8488. https://doi.org/10.31768/2312-8852.2016.38(2):84-88
  48. Chekhun V.F., Lozovska Y.V., Naleskina L.A., Borikun T.V., Burlaka A.P., Todor I.N., Demash D.V., Yalovenko T.M., Zadvornyi T.V., Pavlova A.O., Storchay D.M., Lukianova N.Yu. Modifying effects of 5-azacytidine on metal-containing proteins profile in Guerin carcinoma with different sensitivity to cytostatics. Experimental Oncology 2016; 38(4):283-287. https://doi.org/10.31768/2312-8852.2016.38(4):283-287
  49. Lykhova A., Kudryavets Yu., Strokovska L., Bezdenezhnykh N., Semesiuk N., Adamenko I. Zaharuk J., Vorontsova A. Suppression of proliferation, tumorigenicity and metastasis of lung cancer cells after their transduction by interferon-beta gene in baculovirus vector. Cytokine, 2015. Vol.71. P. 318-326. https://doi.org/10.1016/j.cyto.2014.10.029